Regeneron backs $75M series A for antibody upstart Infinimmune
Biotech startup Infinimmune secures $75 million in Series A funding to develop human-derived antibodies targeting atopic dermatitis and inflammatory diseases.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 3.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: BioPharma Dive · Longevity.Technology · Business Wire · Endpoints News · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Infinimmune has closed a $75 million Series A financing round supported by Regeneron to advance its pipeline of human-derived antibody therapies. The company focuses on re-engineering immune memory to facilitate tissue repair and create alternatives for conditions such as eczema, currently addressed by treatments like Dupixent.
Regeneron’s participation highlights an active interest in the antibody space, a sector where Endpoints News notes major financial maneuvers, including a $2 billion upfront payment by Lilly for vaccine biotechs. BioPharma Dive notes the clinical ambition to outperform existing treatments for atopic dermatitis, while Longevity.Technology focuses on the underlying science of immune memory.
The specific composition of the drug candidate pipeline and the anticipated timeline for entry into human clinical trials are not established in current reports. Coverage does not yet specify which individual inflammatory diseases beyond atopic dermatitis are prioritized for treatment.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Coverage (5)
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczema BioPharma Dive · 7h ago
- Re-engineering immune memory for tissue repair Longevity.Technology · 7h ago
- Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease Business Wire · 7h ago
- Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M Endpoints News · 7h ago
- Regeneron backs $75M series A for antibody upstart Infinimmune Fierce Biotech · 7h ago
The obvious questions
How much funding did Infinimmune raise?
The company raised $75 million in Series A financing.
What is the primary focus of the new antibody drugs?
The pipeline targets atopic dermatitis and other inflammatory diseases using human-derived antibodies.
Which major company is backing the financing?
Regeneron is an investor in the $75 million series A round.
Topics
Related trends
Stanford AI virus study raises specter of bioweapon risk
A Stanford study has used AI to create 16 new viruses that never existed in nature, raising concerns about bioweapon risks.
AI creates first synthetic viruses
For the first time, AI has designed viruses that do not exist in nature.
Experimental Cancer Drug Force-Feeds Tumors Sugar Until They Choke
A newly developed covalent PFKL activator forces cancer cells to consume excess sugar, effectively stuntng tumor growth through metabolic overload.
Stimulation modulates gene-linked cell assemblies in the human brain
Researchers have discovered how electrical stimulation affects neurons and gene activity in living human brain tissue.
Gene-edited beagles may offer a future option for people with dog allergies
Gene-edited beagles may soon offer a future option for people with dog allergies
Cancer-fighting antibodies with a one-two punch take aim at tumours
Engineered bispecific antibodies are targeting B-cell lymphoma by simultaneously engaging tumor cells and activating macrophages to destroy them.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.